Research Progress of Nano-drug Delivery System in Prostate Cancer br
Xue-Yi Liu,Yi Hao,Hui-Jia Song,Tie Chong,Rui-Xia Gao
DOI: https://doi.org/10.16476/j.pibb.2021.0361
2022-01-01
PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
Abstract:Prostate cancer(PCa)is the most frequent genitourinary cancer in men globally.The primary clinicaltreatment options for PCa are surgery,endocrine therapy,radiation,and chemotherapy.The nano-drug deliverydevice provides improved tumor targeting and controlled release features.The capacity to passively target tumorsviagreater permeability and retention(EPR)and increased active targeting by modification of antibodies,peptides,aptamers,or small molecules to identify particular organ or cell receptors can give further advancedbenefits.The design,assembly,and surface modification of nano-drug delivery devices confer differenttherapeutic effects in malignancies.Organic such as micelles,nanogels and dendrimers and inorganic such ascarbon nanotubes,gold nanoparticles,magnetic nanoparticles,mesoporous dioxide silicon nanoparticles,andquantum dots nanocarriers are the most common forms of nanocarriers.Traditional prostate cancer therapiesinclude drawbacks such as adverse effects,minimal effectiveness,and inadequate absorption.Chemotherapy canresult in the development of drug resistance in prostate cancer,hence the development of new,effective,customized therapies is essential.Because of their intrinsic nanoscale features,nano-drug delivery systems,suchas nano-delivery systems paired with chemotherapy,radiation,photodynamic treatment,and hyperthermia,canincrease the therapeutic benefits of conventional therapeutic agents.Such therapies have the potential tosignificantly increase the survival rate of prostate cancer patients.This article discusses sophisticated nano-drugdelivery technologies for PCa treatment,as well as its future potentia